Frequency of symptoms in patients with suspected hyperprolactinemia admitted to a private psychiatric clinic in Recife
DOI:
https://doi.org/10.56102/afmo.2024.305Keywords:
Antipsychotropic drugs, Hyperprolactinemia, Macroprolactinemia, Psychiatric patientsAbstract
Objective: To investigate the symptoms of patients with suspected hyperprolactinemia admitted to a private psychiatric clinic in Recife. Methods: This cross-sectional and descriptive study used non probabilistic sampling and collected data from January to March 2023 using an in-person questionnaire. Participants undergoing clinical rehabilitation for antipsychotic therapy were assessed for the presence of hyperprolactinemia. We consulted medical records to collect data on the medications in use. Data was collected using Excel 2010 and SPSS version 22.0. Results: A total of 51 hospitalized patients aged between 16 and 87 years (SD ± 18.3) were included. Approximately 25% of the participants reported symptomatology commonly associated with hyperprolactinemia, including gynecomastia (53.8%), impaired libido (38.5%), and galactorrhea (7.7%). The medications biperidenhydrochloride and quetiapine hemifumarate were the most prevalent among patients who had complaints of gynecomastia. In contrast, quetiapine hemifumarate, zolpidem hemitartrate, and alprazolam were most frequently used by those reporting impaired libido. Conclusions: This study verified the prevalence of symptoms associated with hyperprolactinemia in patients using antipsychotics admitted to a psychiatric clinic.
References
Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019; 13;8(12):2203. doi: https://doi.org/10.3390/jcm8122203.
Lu Z, Sun Y, Zhang Y, Chen Y, Guo L, Liao Y, Kang Z, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Transl Psychiatry. 2022 Jul 5; 12(1):267. doi: https://doi.org/10.1038/s41398-022-02027-4.
Brand BA, Haveman YRA, de Beer F, de Boer JN, Dazzan P, Sommer IEC. Antipsychotic medication for women with schizophrenia spectrum disorders. Psychol Med. 2022 Mar; 52(4):649-663. doi: https://doi.org/10.1017/S0033291721004591.
Ruljancic N, Bakliza A, Vuk Pisk S, Geres N, Matic K, Ivezic E, et al. Antipsychotics-induced hyperprolactinemia and screening for macroprolactin. Biochem Med (Zagreb). 2020; 31(1): 1-8. doi: https://doi.org/10.11613/BM.2021.010707.
Rizzo LFL, Mana DL, Serra HA, Danilowicz K. Hyperprolactinemia associated with psychiatric disorders. Medicina (B Aires). 2020; 80(6):670-680. PMID: 33254112.
Nahas EAP, Nahás-Neto J, Pontes A, Dias R, Fernandes CE. Estados hiperprolactinêmicos: inter-relações com o psiquismo. Arch Clin Psychiatry (São Paulo). 2006; 33(2). doi: https://doi.org/10.1590/S0101-60832006000200006.
Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003; 16;169(6): 575-81. PMID: 12975226; PMCID: PMC191295.
Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019; 109(1): 7-19. doi: https://doi.org/10.1159/000499694.
Llácer JMB, Hortelano AM, Albelda BR. Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics. Int J Psychiatry Clin Pract. 2019 Sep; 23(3):189-193. doi: https://doi.org/10.1080/13651501.2019.1576905.
Barata PC, Santos MJ, Melo JC, Maia T. Olanzapine-Induced Hyperprolactinemia: Two Case Reports. Front Pharmacol. 2019 Jul 29; 10:846. doi: https://doi.org/10.3389/fphar.2019.00846.
Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021 May 6; 78(10):862-871. doi: https://doi.org/10.1093/ajhp/zxab065.
Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, McCormick PJ, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther. 2018 Dec; 192:20-41. doi: https://doi.org/10.1016/j.pharmthera.2018.06.012.
Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014; 28(5): 421-53. doi: https://doi.org/10.1007/s40263-014-0157-3.
Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, et al. Prevalência de hiperprolactinemia na esquizofrenia: associação com tratamento antipsicótico típico e atípico. J Clin Psychiatry. 2004; 65(11): 1491-8. doi: https://doi.org/10.4088/jcp.v65n1108.
di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. Pituitary. 2020 Jun; 23(3):314-321. doi: https://doi.org/10.1007/s11102-020-01041-3.
Bushe C, Shaw M, Peveler RC. Uma revisão da associação entre o uso de antipsicóticos e hiperprolactinemia. J Psychopharmacol. 2008; 22 (2 suplementos) : 46-55. doi: https://doi.org/10.1177/0269881107088435
Haddad PM, Wieck A. Hiperprolactinemia induzida por antipsicóticos: mecanismos, características clínicas e manejo. Drogas. 2004; 64(20):2291-314. doi: https://doi.org/10.2165/00003495-200464200-00003.
Edinoff AN, Silverblatt NS, Vervaeke HE, Horton CC, Girma E, Kaye AD, Kaye A, et al. Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications. Psychopharmacol Bull. 2021 Mar; 16;51(2):131-148. PMID: 34092827. PMCID: PMC8146565.
Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res. 2021 Mar 26; 402:113098. https://doi.org/doi:10.1016/j.bbr.2020.113098.
González-Rodríguez A, Labad J, Seeman MV. Antipsychotic-induced Hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13; 101:109941. doi: https://doi.org/10.1016/j.pnpbp.2020.109941.
Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021 May 6; 78(10):862-871. doi: https://doi.org/10.1093/ajhp/zxab065.
Pisk SV, Matić K, Gereš N, Ivezić E, Ruljančić N, Filipčić I. Hyperprolactinemia - side effect or part of the illness. Psychiatr Danub. 2019 Jun; 31(Suppl 2):148-152. PMID: 31158115.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emilly Kelly Paiva Damasceno, Gabriel José Paiva Aldeman, Andréia Veras Gonçalves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Esta licença permite que outros distribuam, remixem, adaptem e desenvolvam seu trabalho, mesmo comercialmente, desde que creditem a revista pela criação original.
